Skip to main content
. 2014 Dec;351(3):549–558. doi: 10.1124/jpet.114.216903

Fig. 3.

Fig. 3.

Inhibitors of ALK3 [(A) LDN, (B) DMH2, (C) VU5350] enhance hepatocyte proliferation 48 hours after PH, whereas an inhibitor of ALK2 [(D) VU0469381] does not. Low-dose LDN (0.6 mg/kg b.i.d.) did not affect hepatocyte proliferation compared with control mice (A). Increasing the dose to 2 mg/kg increased proliferation rates from the control level of 13.7 to 22% (P = 0.104). At 6 mg/kg, the rate rose to 31% (P = 0.001). Low-dose DMH2 (B) (0.5 mg/kg b.i.d.) did not increase hepatocyte proliferation, but higher dose (2 mg/kg) doubled hepatocyte proliferation from 13.7 to 26.9% (P = 0.027). Increasing VU5350 (C) from 2 to 20 mg/kg also increased hepatocyte proliferation to nearly double with the larger dose (P = 0.01 at 20 mg/kg). In contrast, VU0469381 (D) led to a decrease in hepatocyte proliferation at the highest dose (13.7 versus 8.2%, P = 0.035). *P < 0.05; ***P < 0.001.